NexImmune Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer
January 09, 2020 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
NexImmune Receives IND Clearance for Phase 1/2 Trial in Relapsed / Refractory Multiple Myeloma
December 19, 2019 07:30 ET
|
NexImmune, Inc.
IND clearance enables commencement of clinical trial to evaluate NEXI-002 in Multiple Myeloma patients who have failed >3 previous lines of therapyFDA action represents the Company’s second IND...
NexImmune Appoints Sol Barer as Chairman of the Board of Directors
December 16, 2019 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...
NexImmune Management to Present at Upcoming Conferences
December 02, 2019 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive...
NexImmune Receives IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
October 31, 2019 07:30 ET
|
NexImmune, Inc.
IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplantIND clearance validates Company’s Artificial...
NexImmune Management to Present at the Jefferies Healthcare Conference
June 04, 2019 09:47 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, NexImmune’s Chief Executive...
Multiple Myeloma Research Foundation (MMRF) Venture Philanthropy Fund Invests in NexImmune to Advance Novel Immunotherapy Candidate Into Clinical Trials
April 29, 2019 07:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new...
NexImmune Management to Present at Upcoming Conferences
April 05, 2019 06:30 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, Neximmune’s Chief Executive...
NexImmune Granted Key US Patent for Core E+E Technology
December 11, 2018 08:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office...
NexImmune Completes Sr. Leadership Team with New VP Hires
December 04, 2018 08:00 ET
|
NexImmune, Inc.
Naimish Pandya, MD assumes role of VP & Head, Clinical DevelopmentAlex Matschiner, MS ChE assumes role of VP, Protein Process Development GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) --...